• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Adare Pharma Solutions

    Flow Sciences

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Reed-Lane

    Adare Pharma Solutions

    Alcami

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Developing Translational Biologics for Brain Disorders

    The future of CNS therapies

    Developing Translational Biologics for Brain Disorders
    Related CONTENT
    • Innovent, Hutchison MediPharma in Drug Combo Collaboration
    • Coeptis Pharma to Acquire Elto Pharma
    • Cambrex Buys Avista for $252M
    • Pharma Future: Trends to Watch
    • Sanofi, Denali Enter Collaboration
    Antti Nurmi, Charles River Discovery Services, Kuopio, Finland11.30.18
    To put it simply, neurological diseases are challenging. The mechanisms of brain diseases are highly complex and intertwined with mechanisms of aging, genetics and environmental factors.

    Alzheimer’s presents one of the starkest examples of this. Its complexity has thus far prevented researchers from developing an effective therapy that can slow or stop the progression of symptoms or prevent the disease from occurring. It is a neurological disorder filled with unknowns. We do not know, for example, what the relationship is between the hallmarks of Alzheimer’s, including brain atrophy and over-expression of amyloid plaques, and the cognitive decline that occurs in people with this devastating condition.

    What we do know is the toll Alzheimer’s is taking on families. In the United States alone, 5.7 million people are living with the disease, and their caregivers (including family) provide 18.4 billion hours of care, valued at over $232 billion. The hunt for solutions to this growing public health problem is incredibly important.

    Applying Biological Therapies in CNS
    The majority of therapeutic approaches to central nervous system (CNS) diseases, including Alzheimer’s, have relied on small molecules aimed at specific targets, such as pathways, enzymes or receptors. These drug candidates have been identified as potential ways of modulating biological processes in a diseased brain by irreversibly changing neurochemical signals and altering the expression, aggregation or clearance of disease-related proteins. In this manner, small molecules have been successfully applied to alleviate symptoms in a variety of neurological diseases. For example, in Parkinson’s disease, the L-DOPA treatment is standard of care for patients and helps them to manage common motor symptoms, including tremors and dyskinesia. However, while L-DOPA treats these symptoms, it does not change the course of the disease.

    The majority of treatments targeted for neurological diseases are small molecules of this nature—aimed at managing specific symptoms. Meanwhile, truly disease-modifying therapies have not been successfully developed for human use. There is, however, a new dawn for neuroscience drug development using biological therapies. These large-molecule drugs (antibodies, gene and cellular therapies, and enzyme replacement therapies) have shown success in other therapeutic areas, including rheumatoid arthritis and various forms of cancer. In CNS, the big obstacle currently is how to get these large molecules to the brain.

    Getting Through the Blood Brain Barrier
    The anatomy and structure of the central nervous system presents a unique challenge in treating diseases of the brain effectively. The blood-brain barrier limits how molecules cross to the brain. There is good reason for this. The blood-brain barrier protects the brain from harmful molecules and microbes that can compromise brain function. It also, unfortunately, prevents large molecule biologics and other large molecules from getting into the brain.

    Researchers are trying to get around this barrier in innovative ways. One way is to use harmless viruses to deliver genes to brain cells and then use those cells to take up the extrachromosomal DNA and produce the desired large molecules. The evolution of biologics therapies in neuroscience has sparked research to address the challenges of utilizing large molecules to enter and to deliver a desired “payload” to brain tissue. Luckily, there are biological mechanisms, both active and passive, that can enhance the transportation of larger molecules through the blood-brain barrier. There are also non-invasive brain manipulations that can be introduced to facilitate the entry of molecules to the CNS in a controlled fashion.

    One of these latest non-invasive techniques is focused ultrasound, which can be used to open the blood-brain barrier transiently, and is considered a safe method to enhance the transfer of desired molecules from the blood stream to the brain tissue. Future research and development will tell if these technologies will be important tools to deliver biologic therapies that would otherwise be obstructed by the blood-brain barrier.

    Utilizing Human Stem Cells
    Currently, the majority of the treatments developed for neurological conditions have not been efficacious or safe in clinical trials. One of the proposed obstacles to the successful development of a translational biological therapy is the use of non-human species as model organisms. From a human disease perspective, some of the currently utilized research models are more relevant than others, but they are still models.
     
    As an alternative strategy, we are seeing a dramatic increase in use of inducible pluripotent stem cells (iPSCs), which have properties closer to patients than any non-human cells. iPSCs can be matured and differentiated to essentially any cell type, which adds an element of significant human relevance to the research. Increasing numbers of CNS disease-related drug development programs use iPSCs to explore mechanisms and effects of new therapies, hopefully leading to the successful development of effective therapies.

    Cellular therapies are also an emerging tool in neuroscience research. The notion that undifferentiated cells of human origin could potentially replace damaged or unhealthy cells of a diseased brain is under intense research. Initial, albeit exploratory clinical research, suggests that in certain diseases and conditions, cellular therapies may be a therapeutic option in the future.

    The Future of CNS Therapies
    Future therapies for neurological diseases will have to employ a diverse range of approaches, utilizing large molecules, cell therapies or gene therapies. There has been a substantial increase in the number of biologics in drug development in recent years, and its prevalence continues to grow. According to Citeline, 24 percent of the neurological candidates in the preclinical pipeline are biologics. Despite the challenges present in accessing the brain, more biological therapies will be explored and developed for neurological diseases in the future, as they provide a number of options to explore for highly complex, but also chronic and slowly progressing, brain diseases.



     
    Antti Nurmi has over 15 years of experience in the life science industry, with the last 10 spent in various roles of scientific leadership roles at Charles River. He earned his PhD from the University of Kuopio in Finland, where his work focused on brain research and the molecular mechanisms behind stroke pathology. He received his MSc in physiology from the University of Joensuu, Finland, where he specialized in cardiac electrophysiology (particularly ion channel physiology and the use of patch-clamping techniques). Dr. Nurmi has published on a variety of topics ranging from cardiac ion channel physiology to therapeutic approaches against disease pathology in stroke and Alzheimer’s disease.
    Related Searches
    • Development
    • patients
    • ion channel
    • cell therapies
    Suggested For You
    Innovent, Hutchison MediPharma in Drug Combo Collaboration Innovent, Hutchison MediPharma in Drug Combo Collaboration
    Coeptis Pharma to Acquire Elto Pharma Coeptis Pharma to Acquire Elto Pharma
    Cambrex Buys Avista for $252M Cambrex Buys Avista for $252M
    Pharma Future: Trends to Watch Pharma Future: Trends to Watch
    Sanofi, Denali Enter Collaboration Sanofi, Denali Enter Collaboration
    Strategic Discovery Strategic Discovery
    HPAPI Market Trends HPAPI Market Trends
    Codiak BioSciences Appoints EVP Codiak BioSciences Appoints EVP
    22	Biogen 22 Biogen
    Takeda, Ovid Detail Clinical Development Program Takeda, Ovid Detail Clinical Development Program
    Skyhawk, Celgene in Strategic Discovery and Development Pact Skyhawk, Celgene in Strategic Discovery and Development Pact
    Biogenerics Progress Biogenerics Progress
    Alexion, Complement Enter Partnership Alexion, Complement Enter Partnership

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20


    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20


    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20

    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Gelest CEO Elected to National Academy of Engineering
    PPG Appoints Tony Wu as VP, Automotive Refinish, Asia
    PPG Appoints John Bruno as VP, Investor Relations
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login